CellaVision (CEVI.ST)

Executive Summary

CellaVision is a world-leading provider of digital hematology microscopy solutions, headquartered in Lund, Sweden. The company offers a comprehensive suite of analyzers, instruments, reagents, and software that automate the workflow in hematology laboratories of all sizes, covering both human and animal blood and body fluid samples. With a presence in over 60 countries and a strong installed base, CellaVision has established itself as a key player in the diagnostic hematology market. The company's solutions enable faster, more accurate, and standardized morphological analysis, reducing manual workload and improving diagnostic confidence. CellaVision's proprietary technology, including artificial intelligence algorithms for cell recognition, positions it well to benefit from the ongoing digital transformation in laboratory medicine. As a publicly traded company on the Stockholm Stock Exchange (ticker: CEVI.ST) with a valuation of approximately $3 billion, CellaVision demonstrates robust financial health and a clear growth trajectory. The company's focus on innovation and its scalable business model underline its potential for sustained expansion in both human and veterinary diagnostics.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation digital hematology analyzer with enhanced AI capabilities80% success
• 2027Expansion into veterinary hematology market through strategic partnerships or acquisitions60% success
• Q4 2026FDA clearance for new software algorithm for automated detection of rare blood cells70% success